{"id":4413,"date":"2019-03-26T03:03:58","date_gmt":"2019-03-26T03:03:58","guid":{"rendered":"https:\/\/www.erdheim-chester.org\/?post_type=study_trials&#038;p=4413"},"modified":"2020-11-03T20:48:56","modified_gmt":"2020-11-03T20:48:56","slug":"dabrafenibe-e-trametinibe-no-tratamento-de-pacientes-com-doenca-de-erdheim-chester-com-mutacoes-no-gene-braf-v600","status":"publish","type":"study_trials","link":"https:\/\/www.erdheim-chester.org\/pt\/study_trials\/dabrafenib-and-trametinib-in-treating-patients-with-erdheim-chester-disease-with-braf-v600-mutations\/","title":{"rendered":"Dabrafenibe e trametinibe no tratamento de pacientes com doen\u00e7a de Erdheim-Chester portadores de muta\u00e7\u00f5es no gene BRAF V600"},"content":{"rendered":"<p><strong>Objetivo do estudo:&nbsp; <\/strong>Este estudo de fase II investiga a efic\u00e1cia e a seguran\u00e7a do tratamento com dabrafenibe e trametinibe em pacientes com doen\u00e7a de Erdheim-Chester portadores de muta\u00e7\u00f5es no gene BRAF V600.<br \/>\n<strong>Patrocinador:<\/strong>&nbsp; Instituto Nacional do C\u00e2ncer (NCI)<br \/>\n<strong>Informa\u00e7\u00f5es de contato para o per\u00edodo de teste:<\/strong>&nbsp; Coordenadora do estudo: Sra. Abha Adat, aadat@mdanderson.org, ou o Pesquisador Principal Filip Janku, 713-563-1930, FJanku@mdanderson.org.<br \/>\n<strong>Envolvimento solicitado do paciente:<\/strong>&nbsp; Pacientes com ECD portadores da muta\u00e7\u00e3o BRAF V600 que n\u00e3o tenham recebido tratamento pr\u00e9vio com um inibidor de BRAF ou de MEK e que tenham 18 anos ou mais.<br \/>\n<strong>Centros conhecidos que aceitam pacientes com ECD no estudo:<\/strong>&nbsp; MD Anderson, Houston, TX<br \/>\n<strong>Identificador do ClinicalTrials.gov:<\/strong>&nbsp; NCT03794297<\/p>","protected":false},"excerpt":{"rendered":"<p>Study Objective:&nbsp; This phase II trial investigates the efficacy and safety of dabrafenib and trametinib treatment in patients with Erdheim Chester disease that have BRAF V600 gene mutations. Sponsor:&nbsp; National [&hellip;]<\/p>\n","protected":false},"featured_media":0,"parent":0,"menu_order":0,"template":"","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","cybocfi_hide_featured_image":"","wds_primary_study_trials_cat":0,"_links_to":"","_links_to_target":""},"study_trials_cat":[32],"class_list":["post-4413","study_trials","type-study_trials","status-publish","hentry","study_trials_cat-drug-trial"],"_links":{"self":[{"href":"https:\/\/www.erdheim-chester.org\/pt\/wp-json\/wp\/v2\/study_trials\/4413","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.erdheim-chester.org\/pt\/wp-json\/wp\/v2\/study_trials"}],"about":[{"href":"https:\/\/www.erdheim-chester.org\/pt\/wp-json\/wp\/v2\/types\/study_trials"}],"wp:attachment":[{"href":"https:\/\/www.erdheim-chester.org\/pt\/wp-json\/wp\/v2\/media?parent=4413"}],"wp:term":[{"taxonomy":"study_trials_cat","embeddable":true,"href":"https:\/\/www.erdheim-chester.org\/pt\/wp-json\/wp\/v2\/study_trials_cat?post=4413"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}